Unadjusted Plasma Renin Activity as a "First-Look" Test to Decide Upon Further Investigations for Primary Aldosteronism

Journal of Clinical Hypertension

Volumn 17, Issue 7, 2015, Pages 541-546

  Rye, Peter ^a   Chin, Alex ^b   Pasieka, Janice ^b   So, Benny ^b   Harvey, Adrian ^b   Kline, Gregory ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANTIHYPERTENSIVE AGENT; MINERALOCORTICOID ANTAGONIST; RENIN; SPIRONOLACTONE;

ADULT; BLOOD; BODY MASS; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; MALE; MIDDLE AGED; RETROSPECTIVE STUDY;

ADULT; ALDOSTERONE; ANTIHYPERTENSIVE AGENTS; BODY MASS INDEX; FEMALE; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RENIN; RETROSPECTIVE STUDIES; SPIRONOLACTONE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84934443164     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12523     Document Type: Article

References (34)

1. Rossi GP, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary aldosteronism in 1125 hypertensive patients. J Am Coll Cardiol. 2006;48:2293-2300.
2. Zarnegar R, Young WF, Lee J, et al. The aldosteronoma resolution score: predicting complete resolution of hypertension after adrenalectomy for aldosteronoma. Ann Surg. 2008;247:511-518.
3. Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243-1248.
4. Stowasser M, Sharman J, Leano R, et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab. 2005;90:5070-5076.
5. Chao CT, Wu VC, Kuo CC, et al. Diagnosis and management of primary aldosteronism: an updated review. Ann Med. 2013;45:375-383.
6. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:3266-3281.
7. Schwartz GL, Turner ST. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem. 2005;51:386-394.
8. Nishikawa T, Saito J, Omura M. Prevalence of primary aldosteronism: should we screen for primary aldosteronism before treating hypertensive patients with medication? Endocr J. 2007;54:487-495.
9. Schwartz GL, Chapman AB, Boerwinkle E, et al. Screening for primary aldosteronism: implications of an increased plasma aldosterone/renin ratio. Clin Chem. 2002;48:1919-1923.
10. Padfield PL. Prevalence and role of a raised aldosterone to renin ratio in the diagnosis of primary aldosteronism: a debate on the scientific logic of the use of the ratio in practice. Clin Endocrinol. 2003;59:422.
11. Nanba K, Tamanaha T, Nakao K, et al. Confirmatory testing in primary aldosteronism. J Clin Endocrinol Metab. 2012;97:1688-1694.
12. Mulatero P, Stowasser M, Loh KC, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004;89:1045-1050.
13. Montori VM, Schwartz GL, Chapman AB, et al. Validity of the aldosterone-renin ratio used to screen for primary aldosteronism. Mayo Clin Proc. 2001;76:877-882.
14. Mulatero P, Rabbia F, Milan A, et al. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension. 2002;40:897-902.
15. Stowasser M, Taylor PJ, Pimenta E, et al. Laboratory investigation of primary aldosteronism. Clin Biochem Rev. 2010;31:39-56.
16. Mulatero P, Monticone S, Veglio F. Diagnosis and treatment of primary aldosteronism. Rev Endocr Metab Disord. 2011;12:3-9.
17. Fischer E, Beuschlein F, Bidlingmaier M, Reincke M. Commentary on the Endocrine Society Practice Guidelines: consequences of adjustment of antihypertensive medication in screening of primary aldosteronism. Rev Endocr Metab Disord. 2011;12:43-48.
18. Kline GA, Pasieka JL, Harvey A, et al. Medical or surgical therapy for primary aldosteronism: post-treatment follow up as a surrogate measure of comparative outcomes. Ann Surg Oncol. 2013;20:2274-2278.
19. Kline GA, Pasieka JL, Harvey A, et al. High-probability features of primary aldosteronism may obviate the need for confirmatory testing without increasing false positive diagnoses. J Clin Hypertens (Greenwich). 2014;16:488-496.
20. Paul R, Mordhorst J, Busch R, et al. Adrenal sparing surgery during radical nephrectomy in patients with renal cell cancer: a new algorithm. J Urol. 2001;166:59-62.
21. Küpers EM, Amar L, Raynaud A, et al. A clinical prediction score to diagnose unilateral primary aldosteronism. J Clin Endocrinol Metab. 2012;97:3530-3537.
22. Rossi GP, Bernini G, Desideri G, et al. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension. 2006;48:232-238.
23. Nanba K, Tsuiki M, Sawai K, et al. Histopathological diagnosis of primary aldosteronism using CYP11B2 immunohistochemistry. J Clin Endocrinol Metab. 2013;98:1567-1574.
24. Jackson RV, Lafferty A, Torpy DJ, Stratakis C. New genetic insights in familial hyperaldosteronism. Ann N Y Acad Sci. 2002;970:77-88.
25. Tomaschitz A, Pilz S. Aldosterone to renin ratio-a reliable screening tool for primary aldosteronism? Horm Metab Res. 2010;42:382-391.
26. Sirén J, Välimäki M, Huikuri K, et al. Adrenalectomy for primary aldosteronism: long-term follow-up study in 29 patients. World J Surg. 1998;22:418-421.
27. Hannemann A, Wallaschofski H. Prevalence of primary aldosteronism in patient's cohorts and in population-based studies-a review of the current literature. Horm Metab Res. 2012;44:157-162.
28. Tanabe A, Naruse M, Takagi S, et al. Variability in the renin/aldosterone profile under random and standardized sampling conditions in primary aldosteronism. J Clin Endocrinol Metab. 2003;88:2489-2494.
29. Hirohara D, Nomura K, Okamoto T, et al. Performance of the basal aldosterone to renin ratio and of the renin stimulation test by furosemide and upright posture in screening for aldosterone-producing adenoma in low renin hypertensives. J Clin Endocrinol Metab. 2001;86:4292-4298.
30. Gallay BJ, Ahmad S, Xu L, et al. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis. 2001;37:699-705.
31. Oelkers W, Diederich S, Bähr V. Primary hyperaldosteronism without suppressed renin due to secondary hypertensive kidney damage. J Clin Endocrinol Metab. 2000;85:3266-3270.
32. Alvarez-madrazo S, Padmanabhan S, Mayosi BM, et al. Familial and phenotypic associations of the aldosterone Renin ratio. J Clin Endocrinol Metab. 2009;94:4324-4333.
33. Olivieri O, Ciacciarelli A, Signorelli D, et al. Aldosterone to Renin ratio in a primary care setting: the Bussolengo study. J Clin Endocrinol Metab. 2004;89:4221-4226.
34. Stowasser M, Gordon RD. Aldosterone excess, hypertension, and chromosome 7p22: evidence continues to mount. Hypertension. 2007;49:761-762.